Targeting mTOR in Pancreatic Ductal Adenocarcinoma

Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited; however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data have shown that inhibition of mammalian target of rapamycin (mTOR) in spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Iriana, Sentia, Ahmed, Shahzad, Gong, Jun, Annamalai, Alagappan Anand, Tuli, Richard, Hendifar, Andrew Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843105/
https://www.ncbi.nlm.nih.gov/pubmed/27200288
http://dx.doi.org/10.3389/fonc.2016.00099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843105/
https://www.ncbi.nlm.nih.gov/pubmed/27200288
http://dx.doi.org/10.3389/fonc.2016.00099

Ejemplares similares